Trial Profile
A phase 3, multicenter, randomized, double-blind, comparative study to evaluate the safety and efficacy of ceftaroline [ceftaroline fosamil] versus ceftriaxone in the treatment of adult subjects with community-acquired pneumonia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2019
Price :
$35
*
At a glance
- Drugs Ceftaroline fosamil (Primary) ; Ceftriaxone
- Indications Community-acquired pneumonia
- Focus Registrational; Therapeutic Use
- Acronyms FOCUS-2; FOCUS-II
- Sponsors Cerexa; Forest Laboratories
- 28 Dec 2018 Results assessing safety and tolerability of ceftaroline fosamil q8h and q12h regimens using data from 6 phase three trials (NCT01499277, NCT00424190, NCT00423657, NCT01371838, NCT00621504 and NCT00509106) published in the Journal of Antimicrobial Chemotherapy
- 24 Apr 2018 Results assessing comparison of safety profile of two regimens of ceftaroline fosamil by using data from six phase III studies (COVERS, CANVAS 1, CANVAS 2, FOCUS 1, FOCUS 2, and asian CAP) presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
- 05 Jun 2017 Results of subgroup analysis from two phase III studies (FOCUS-1 and FOCUS-2) presented at the ASM Microbe 2017.